**Specifications table**TableSubject area*Veterinary medicine, Biomedicine*More specific subject area*Proteomics, statistics, bioinformatics, immunoassays*Type of data*Excel files, graphs, figures*How data was acquired1.*LC-MS/MS analysis was performed using Ultimate 3000 RSLCnano system (Dionex, Germering, Germany) coupled to Q Exactive Plus mass spectrometer (Thermo Fisher Scientific, Bremen, Germany)*.2.*Acute phase proteins absolute quantification was performed using ELISA tests (for AGP, SAA) and radial immunodiffusion (for OVT)*.Data format*Integration of raw and analyzed data*Experimental factors*Non-depleted plasma samples*Experimental features*Quantitative proteomic, bioinformatic and immunoassay analyses of chicken serum*Data source location*University of Glasgow Cochno Farm & Research Centre, Glasgow, United Kingdom*Data accessibility*The mass spectrometry proteomics raw data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD009399MS* (<http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD009399>). *All other data are available within this article.*

**Value of the data**•This data provides information about changes in plasma proteome in chickens challenged with *Escherichia coli* lipopolysaccharide during 72 h with the emphasis on acute phase proteins such as alpha-1-acid glycoprotein (AGP), serum amyloid A (SAA) and ovotrensferrin (OVT).•Peptide/protein information and pathway analysis datasets might be useful as a basis for future targeted analysis of proteins deregulated during inflammation.•The data can be useful for other researchers investigating inflammation or pathophysiological mechanisms in veterinary medicine as well as in biomedical research.

1. Data {#s0005}
=======

Protein and peptide identifications, as well as their corresponding peptide spectrum matches (PSMs), obtained by label-based proteomic approach, in plasma from chicken challenged with *Escherichia coli* lipopolysacharride (LPS) endotoxin (2 mg/kg body weight) pre (0 h) and at 12, 24, 48, and 72 h post injection along with plasma from a control group (N=6) challenged with sterile saline are reported, with the corresponding peptide spectrum matches (PSMs). Furthermore, relative quantification data after statistical analysis together with subsequent pathway analysis results and immunoassays data are also presented.

Results of analyze performed on this dataset has been represented in different figures and tables included in this Data in Brief article.

[Fig. 1](#f0005){ref-type="fig"} represent fold changes of proteins between LPS-treated and saline groups, and their associated p-values.Fig. 1Volcano plot for chicken challenged with *Escherichia coli* lipopolysaccharide endotoxin *versus* saline group. Volcano plot of fold changes (x-axis) and their associated log10 transformed p-values (y-axis) for the 571 peptides analysed by LC-MS. Peptides significantly different between saline and LPS groups (log10 p\>1.3) are in black, non-significant peptides (log10 p\<1.3) are in grey.Fig. 1

[Fig. 2](#f0010){ref-type="fig"} represent how time affect proteins quantities in LPS animals.Fig. 2Time-affected proteins in chicken challenged with *Escherichia coli* lipopolysaccharide endotoxin (LPS group). Barplot of the mean and SEM of 19 proteins differentially expressed for the different time points (0 h, 12 h, 24 h, 48 h, 72 h) in LPS group. Proteins have been grouped according to their pattern of expression: A or B and C. Patterns have been defined according to the evolution of fold changes among time.Fig. 2

[Fig. 3](#f0015){ref-type="fig"} represent pathways up and down regulated, associated with LPS treatment.Fig. 3Interactome of pathways differentially expressed between chicken challenged with *Escherichia coli* lipopolysaccharide endotoxin and saline, and their intermediate proteins. Gene ontology analysed pathways and proteins over-represented in LPS compared with saline samples. This analyse have been done with the Cytoscape application ClueGO and the REVIGO tool for GO terms selection. GO terms and proteins over-expressed in LPS are in green, lower-expressed in LPS are in red. GO terms in grey could not be attributed specifically to over or lower expressed terms/proteins. GO terms in bold represent GO terms selected to be the most representative of their GO group defined by the REVIGO tool. The yFiles radial layout algorithm was applied.Fig. 3

[Fig. 4](#f0020){ref-type="fig"} represent pathways affected by time, associated with LPS treatment. Evolution of proteins fold changes (LPS vs saline groups) are represented for each time-affected proteins.Fig. 4Interactome of pathways differentially expressed among time in chicken challenged with *Escherichia coli* lipopolysaccharide (LPS group) and their intermediate proteins. Gene ontology analysed pathways over-represented in the list of 19 proteins differentially expressed among time in LPS group. This analyse have been done with the Cytoscape application ClueGO and the REVIGO tool for GO terms selection. GO terms in bold represent GO terms selected to be the most representative of their GO group defined by the REVIGO tool. For each proteins, 4 fold changes among the 5 different time points have been represented using colour intensity to figure fold change value. Positive fold changes are in green, negative are in red, fold change values close to 0 are in white. Proteins have been gather in 3 groups defined by their fold changes pattern. The A pattern correspond to a quick increase of a protein, then go back to the initial situation, while the pattern B correspond to a quick decrease of a protein and then a go back to the initial situation. The C pattern correspond to a decrease which happen later in the infection process. For each pattern, evolution of one protein mean among time has been represented with histogram to illustrate the pattern properties.Fig. 4

[Fig. 5](#f0025){ref-type="fig"} represent quantification of 3 proteins (α1-acid glycoprotein, SAA, ovotransferrin) performed by ELISA at 5 time points (0, 12, 24, 48 and 72 h).Fig. 5ELISA quantification of alpha-1-acid glycoprotein (AGP), serum amyloid A (SAA), and ovotransferrin (OVT) in different time points. Quantity of each proteins have been represented among time points, for the 2 groups: LPS (continuous line) and saline (dash line). To better visualize difference in SAA, quantities have been transformed by the function log10 for the figure. SEM for each groups and time points have been added. Significance of differences between LPS and saline group for each time point separately have been represented. \*p\<0.05, \*\*p\<0.01 and t: p\>0.05.Fig. 5

[Fig. 6](#f0030){ref-type="fig"} represent differences in fold changes (LPS vs saline) between 4 times points (12, 24, 48, 72 h) and 0 h, to compare ELISA and LS-MS quantification.Fig. 6Comparison of 4 fold changes among 5 time points performed by ELISA and LC-MS on alpha-1-acid glycoprotein (AGP), serum amyloid A (SAA), and ovotransferrin (OVT). Fold changes values have been represented for the 3 proteins to establish a comparison between ELISA and LC-MS quantifications: AGP/ORM1 (A), OVT/TF (B), and SAA/HPS5 (C).Fig. 6

[Table 1](#t0005){ref-type="table"} list proteins significantly different between LPS and saline group, with their associated fold changes and p-values.Table 1Proteins with significantly differential abundances between LPS and saline groups identified using TMT approach.Table 1**Gene Symbol(*****Gallus gallus*****)Protein nameP-value (FDR)Fold Change**HPS5serum amyloid A protein2.20E-031.24SERPINA3alpha-1-antiproteinase[\*](#tbl1fnStar){ref-type="table-fn"}7.89E-071.02HPXhaemopexin[\*](#tbl1fnStar){ref-type="table-fn"}5.35E-060.79ORM1alpha 1-acid glycoprotein1.05E-050.66LCN8extracellular fatty acid-binding protein precursor7.62E-030.65TFovotransferrin3.61E-060.49CPceruloplasmin[\*](#tbl1fnStar){ref-type="table-fn"}1.14E-030.48SMC4condensin complex subunit1.94E-030.47LOC107051143complement C3-like[\*](#tbl1fnStar){ref-type="table-fn"}2.09E-050.43CFDcomplement factor D, partial[\*](#tbl1fnStar){ref-type="table-fn"}1.05E-040.34LOC423629uncharacterized protein LOC423629[\*](#tbl1fnStar){ref-type="table-fn"}1.87E-030.33LOC419851complement regulatory soluble protein9.47E-030.32PIT54PIT 541.17E-040.29LOC100858647beta-microseminoprotein-like[\*](#tbl1fnStar){ref-type="table-fn"}2.99E-030.28FGAFibrinogen alpha chain precursor4.45E-050.26CLUclusterin isoform X1[\*](#tbl1fnStar){ref-type="table-fn"}6.86E-030.21FGBFibrinogen beta chain precursor2.46E-040.21FGGfibrinogen gamma chain precursor1.10E-040.21C3complement C3 precursor1.41E-030.19IGLL1immunoglobulin light chain variable region, partial1.79E-020.18CFHR2complement factor H[\*](#tbl1fnStar){ref-type="table-fn"}1.64E-050.17SPINK5ovoinhibitor2.87E-020.17A2ML4alpha-2-macroglobulin-like protein 1[\*](#tbl1fnStar){ref-type="table-fn"}8.86E-030.17VNN1pantetheinase precursor3.69E-020.17APOHbeta-2-glycoprotein 1 precursor3.50E-030.15FETUBfetuin-B precursor8.55E-060.15PLGplasminogen[\*](#tbl1fnStar){ref-type="table-fn"}3.20E-060.12ATRNattractin isoform X3[\*](#tbl1fnStar){ref-type="table-fn"}3.08E-020.11LOC418892uncharacterized protein2.78E-020.11CST3cystatin precursor2.25E-02−0.10TNCtenascin4.09E-02−0.11ITIH3inter-alpha-trypsin inhibitor heavy chain H3 isoform X1[\*](#tbl1fnStar){ref-type="table-fn"}4.21E-02−0.12AGRNbasement membrane-specific heparan sulfate proteoglycan core protein precursor2.51E-02−0.12ITIH2inter-alpha-trypsin inhibitor heavy chain H2 precursor1.96E-02−0.12IGFALSinsulin-like growth factor-binding protein complex acid labile subunit isoform X1[\*](#tbl1fnStar){ref-type="table-fn"}3.71E-03−0.13HSPG2basement membrane-specific heparan sulfate proteoglycan core protein[\*](#tbl1fnStar){ref-type="table-fn"}1.79E-02−0.13HRGhistidine-rich glycoprotein[\*](#tbl1fnStar){ref-type="table-fn"}1.51E-02−0.14COL5A1alpha 1 (V) collagen2.79E-02−0.14KNG1kininogen-1[\*](#tbl1fnStar){ref-type="table-fn"}1.19E-03−0.14C1QTNF3complement C1q tumor necrosis factor-related protein 3 isoform X1[\*](#tbl1fnStar){ref-type="table-fn"}8.85E-03−0.14F13A1coagulation factor XIII A chain4.15E-02−0.14LUMlumican precursor2.45E-03−0.14AHSGalpha-2-HS-glycoprotein[\*](#tbl1fnStar){ref-type="table-fn"}3.98E-02−0.14GIFhypothetical protein RCJMB04_7i43.80E-02−0.15PROS1vitamin K-dependent protein S[\*](#tbl1fnStar){ref-type="table-fn"}1.42E-02−0.15APOA2apolipoprotein A-II[\*](#tbl1fnStar){ref-type="table-fn"}2.47E-02−0.16ANPEPaminopeptidase, partial2.11E-02−0.16LOC107056848cadherin-5-like, partial[\*](#tbl1fnStar){ref-type="table-fn"}7.56E-03-0.17VTNvitronectin precursor1.59E-05−0.17CL2ribonuclease CL2 precursor1.69E-02−0.17LOC107055759vitamin K-dependent protein S-like[\*](#tbl1fnStar){ref-type="table-fn"}7.86E-03−0.17APOA1apolipoprotein A-I1.64E-05−0.18FBLN1fibulin-1, isoform D precursor3.85E-02−0.18APOA4apolipoprotein A-IV precursor4.10E-04−0.19IL6STinterleukin-6 receptor subunit beta precursor4.32E-05−0.20TFRCchicken transferrin receptor2.19E-04−0.20SPARCbasement-membrane protein 40 precursor3.29E-02−0.20F13Bcoagulation factor XIII B chain isoform X1[\*](#tbl1fnStar){ref-type="table-fn"}9.61E-03−0.20LOC100857892sushi, nidogen and EGF-like domain-containing protein 1 isoform X1[\*](#tbl1fnStar){ref-type="table-fn"}8.56E-03−0.20LOC107050076IgGFc-binding protein-like, partial[\*](#tbl1fnStar){ref-type="table-fn"}4.78E-03−0.21SERPINF1pigment epithelium-derived factor precursor3.03E-06−0.21CLEC3Btetranectin precursor7.32E-03−0.22SERPINC1antithrombin-III[\*](#tbl1fnStar){ref-type="table-fn"}1.39E-06−0.23SERPINA4serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4 precursor3.23E-04−0.23LOC771012coagulation factor X-like[\*](#tbl1fnStar){ref-type="table-fn"}4.19E-03−0.23ENO1alpha-enolase6.46E-03−0.23LOC100858068IgGFc-binding protein-like, partial[\*](#tbl1fnStar){ref-type="table-fn"}2.32E-02−0.23RBP4AE Chain E, Retinol Binding Protein Complexed With Transthyretin2.26E-04-0.25FN1fibronectin, partial9.44E-03−0.26SERPINA5alpha-1-antitrypsin isoform X1[\*](#tbl1fnStar){ref-type="table-fn"}2.49E-04−0.28TGFBItransforming growth factor-beta-induced protein ig-h3 precursor3.84E-06−0.28HBG2beta-globin1.46E-02−0.29LCATlecithin-cholesterol acyltransferase, partial1.14E-02−0.29C4complement C4 precursor3.37E-02−0.30ALPPintestinal-type alkaline phosphatase[\*](#tbl1fnStar){ref-type="table-fn"}1.27E-02−0.30POSTNperiostin precursor3.16E-06−0.32COL1A1collagen alpha-1(I) chain[\*](#tbl1fnStar){ref-type="table-fn"}2.52E-05−0.36SCARA5scavenger receptor class A member 5 isoform X1[\*](#tbl1fnStar){ref-type="table-fn"}1.97E-02−0.36LOC776376pentraxin-related precursor1.82E-02−0.39HBADalpha-D globin3.10E-02−0.43COL6A1collagen alpha-1(VI) chain precursor2.07E-06−0.44CPN2carboxypeptidase N subunit 2[\*](#tbl1fnStar){ref-type="table-fn"}2.11E-05−0.46LRRC15uncharacterized protein LRRC15[\*](#tbl1fnStar){ref-type="table-fn"}2.11E-05−0.46HBAAhemoglobin subunit alpha-A chain7.37E-03−0.48KRT8keratin, type II cytoskeletal 8[\*](#tbl1fnStar){ref-type="table-fn"}3.35E-02−0.50LOC107055417keratin, type II cytoskeletal 8-like, partial[\*](#tbl1fnStar){ref-type="table-fn"}3.35E-02−0.50COL1A2collagen alpha-2(I) chain precursor7.52E-04−0.51[^1][^2]

[Table 2](#t0010){ref-type="table"} list proteins significantly different between LPS and saline group which are affected by time effect, with associated fold changes among time and p-values.Table 2Proteins with significantly differential abundances during time in chicken challenged with *Escherichia coli* lipopolysaccharide endotoxin.Table 2**Gene symbolP value (FDR)Fold change (12 h/0 h)Fold change (24 h/0 h)Fold change (48 h/0 h)Fold change (72 h/0 h)**A2ML41.57E-020.340.440.310.19AHSG1.06E-02−0.43−0.15−0.040.13APOA21.37E-02−0.36−0.49−0.19−0.30C34.39E-020.180.350.350.19CFD1.89E-020.420.610.620.43COL1A13.39E-02−0.62−0.42−0.42−0.23CP3.16E-031.021.050.510.21FGA9.93E-030.290.380.230.03FGB1.03E-020.260.340.240.03FGG9.19E-030.230.330.230.01HPS55.44E-032.271.350.35-0.29HPX7.81E-030.761.201.210.94ITIH24.46E-02−0.19−0.050.020.04LCN81.82E-021.781.020.660.21ORM15.01E-030.931.180.760.42POSTN2.18E-020.06−0.30−0.35−0.15SERPINA34.31E-031.241.350.990.73TF1.54E-020.510.550.410.30TGFBI1.50E-02−0.34−0.52−0.29−0.24

[Table 3](#t0015){ref-type="table"} list GO terms associated by LPS challenge, with their associated p-values.Table 3GO terms over-represented in chicken challenged with *Escherichia coli* lipopolysaccharide endotoxin *vs* saline group.Table 3**GOIDGOTermTerm p-valueGenesClusterRedundantLeaderGroup**GO:0072378blood coagulation, fibrin clot formation1.18E-126No specificGO:0052547**GO:0031589cell-substrate adhesion1.76E-047No specificYesGO:0031589**GO:0015893drug transport6.75E-034NegativeGO:1902042GO:0035987endodermal cell differentiation5.95E-043NegativeGO:0052547GO:0030198extracellular matrix organization6.46E-034NegativeGO:0043062**GO:0043062extracellular structure organization8.25E-046NegativeYesGO:0043062**GO:0030195negative regulation of blood coagulation1.75E-065PositiveYesNAGO:0010951negative regulation of endopeptidase activity9.55E-1816NegativeYesNAGO:2000352negative regulation of endothelial cell apoptotic process4.89E-043PositiveGO:1902042**GO:1902042negative regulation of extrinsic apoptotic signaling pathway via death domain receptors4.17E-043PositiveYesGO:1902042**GO:0031639plasminogen activation3.14E-043PositiveGO:0052547GO:0070527platelet aggregation4.19E-033PositiveYesNAGO:0022409positive regulation of cell-cell adhesion3.36E-034PositiveGO:0031589GO:0045921positive regulation of exocytosis4.19E-033PositiveYesNAGO:0090277positive regulation of peptide hormone secretion4.94E-044PositiveGO:1902042GO:0050714positive regulation of protein secretion4.76E-034PositiveYesNAGO:0045907positive regulation of vasoconstriction6.99E-043PositiveGO:0052547GO:0072376protein activation cascade2.79E-139No specificGO:0052547GO:0016485protein processing1.58E-035PositiveYesNAGO:0030193regulation of blood coagulation6.70E-087No specificYesNAGO:0010810regulation of cell-substrate adhesion9.15E-033NegativeYesNAGO:0051336regulation of hydrolase activity1.52E-1020NegativeGO:0052547**GO:0052547regulation of peptidase activity1.62E-1718NegativeYesGO:0052547**GO:0051592response to calcium ion4.15E-033PositiveGO:1902042GO:0042060wound healing7.79E-0710NegativeYesNA[^3]

[Table 4](#t0020){ref-type="table"} list GO terms associated by LPS challenge and time, with their associated p-values.Table 4GO terms over-represented in chicken challenged with *Escherichia coli* lipopolysaccharide endotoxin during time.Table 4**GOIDGOTermTerm p-valueGenesRedundantLeaderGroup**GO:0006953acute-phase response7.12E-063GO:0072376GO:0010951negative regulation of endopeptidase activity3.40E-054GO:0072376**GO:0072376protein activation cascade6.11E-074YesGO:0072376GO:0034116positive regulation of heterotypic cell-cell adhesion4.60E-073YesGO:0034116**GO:0051592response to calcium ion5.96E-053GO:0072376GO:0070527platelet aggregation5.32E-053YesGO:0072376GO:0045921positive regulation of exocytosis5.32E-053YesGO:0072376GO:0042730fibrinolysis3.15E-063GO:0072376GO:0045907positive regulation of vasoconstriction7.12E-063GO:0072376GO:0050714positive regulation of protein secretion1.72E-043YesGO:0072376GO:0090277positive regulation of peptide hormone secretion4.96E-053GO:0072376GO:0031639plasminogen activation3.15E-063GO:0072376GO:1902042negative regulation of extrinsic apoptotic signaling pathway via death domain receptors3.99E-063GO:0072376GO:2000352negative regulation of endothelial cell apoptotic process4.80E-063GO:0072376[^4]

[Table 5](#t0025){ref-type="table"} present different group and time effects for the proteins SAA, AGP and OVT, quantified by ELISA.Table 5P-values of group and time effects on alpha-1-acid glycoprotein (AGP), serum amyloid A (SAA), and ovotransferrin (OVT) proteins quantified by ELISA.Table 5**ProteinGroupGroup x timeTime - LPS groupTime -- saline group**AGP\<0.001\<0.001\<0.001NSSAA\<0.001\<0.001\<0.001NSOVT\<0.001\<0.001\<0.001NS[^5]

[Table 6](#t0030){ref-type="table"} present results about time effect on proteins AGP, SAA and OVT, between LPS stimulated samples and controls, and inside the LPS-stimulated group.Table 6Time effect for alpha-1-acid glycoprotein (AGP), serum amyloid A (SAA), and ovotransferrin (OVT) proteins quantified by ELISA. A. Effect of group (LPS *versus* saline) for each time point, saline used as reference to compare. B. Effect of time on proteins fold change compared with 0 h (reference level).Table 6**A. Group effect (LPS versus saline) for each time point0 h12 h24 h48 h72 hAGP**Fold change−0.041.291.681.180.96P valueNS\<0.01\<0.01\<0.05NS**SAA**Fold change0.735.211.901.710.01P valueNS\<0.01\<0.01\<0.05NS**OVT**Fold change−0.060.781.050.900.62P valueNS\<0.01\<0.01\<0.01\<0.1  **B. Time effect in LPS group compared with 0 h12 h/0 h24 h/0 h48 h/0 h72 h/0 hAGP**Fold change2.162.111.220.91P value\<0.01\<0.01\<0.05NS**SAA**Fold change5.772.580.44−1.53P value\<0.01\<0.01NSNS**OVT**Fold change1.061.411.130.92P value\<0.01\<0.01\<0.01\<0.01[^6]

2. Experimental design, materials and methods {#s0010}
=============================================

In March and April 2017 one day old, Ross 308 broiler chicks (PD Hook Hatcheries Ltd, Bampton, UK), were fitted with unique wing tags and housed in 4 groups of 14 in adjacent 1 m × 2 m pens on a litter of wood shavings on the University of Glasgow Cochno Farm & Research Centre. Broiler mash and water were available *ad libitum*. From the second day, one group per day was handled and moved into the trial room. All chickens were confirmed to be climatized to handling by 15 days old. Room temperature was maintained within the thermal neutral zone at 18 °C (range 18.0--18.3) and a 20 h:4 h light: dark cycle was implemented.

The experiment commenced when the chickens were 15 days old. Twenty four birds were injected subcutaneously (SC) at time point 0, with *Escherichia coli* lipopolysaccharide (LPS from E. coli O111:B4 purified by phenol extraction, L2630-25MG; Sigma-Aldrich, Dorset, UK) (2 mg/kg body weight) in a volume of 0.5 mL as the treatment group and another 24 birds injected SC by sterile normal saline (0.5 mL) as a control group. There were 5 blood sampling time points; pre (0 h) and post injection (PI) at 12, 24, 48, and 72 h. Plasma was collected from the same 6 chicken in the treated group and from the same 6 chicken in the untreated group, subsequently, at each time point for further analyses by proteomic and immunoassay methods. The remaining 18 birds in each group were not used in the plasma proteome investigation. Approximately 1.2 mL of blood was collected from the wing vein using heparinized tubes at each time point. The heparinised blood was centrifuged (3000g) for 15 min at 4 °C and the plasma aspirated and immediately frozen at −20 °C.

After the trial, all chickens were culled by over dose (1.5--2 mL/bird) *i.v.* injection of barbiturate (Euthatal 200 mg/mL, Merial, Woking, UK). Research was conducted under Home Office license (60/4466), and approved by ethical review of the University of Glasgow, MVLS College Ethics Committee.

3. Proteomic investigation of chicken plasma {#s0015}
============================================

Proteomic analysis of chicken plasma samples was performed by applying TMT-based quantitative gel-free approach as described previously [@bib2]. In brief, after total protein concentration determination using BCA assay (Thermo Scientific, Rockford, USA), 35 µg of total plasma proteins from samples and internal standard (pool of all samples) were diluted to a volume of 50 µL using 0.1 M triethyl ammonium bicarbonate (TEAB, Thermo Scientific, Rockford, USA), reduced by adding 2.5 µL of 200 mM DTT (60 min, 55 °C) (Sigma Aldrich, St. Louis, MO, USA), alkylated by adding 2.5 µL of 375 mM IAA (30 min, room temperature in the dark) (Sigma Aldrich, St. Lois, MO, USA) and acetone-precipitated (addition of 300 µL, overnight, −20 °C). Protein pellets were collected subsequently by centrifugation (8000*g*, 4 °C), dissolved in 50 µL of 0.1 M TEAB and digested using 1 µL of trypsin (1 mg/mL, Promega; trypsin-to-protein ratio 1:35, at 37 °C overnight). TMT sixplex reagents (Thermo Scientific, Rockford, IL, USA) were prepared according manufacturer׳s procedure and an amount of 19 µL of the appropriate TMT label was added to each sample used for the labelling reaction (60 min, room temperature) which was quenched using 5% hydroxylamine (Sigma-Aldrich, St. Louis, MO, USA). Five TMT-modified peptide samples were combined with the internal standard (labelled with TMT *m*/*z* 126) into the new tube, aliquoted, dried and stored at −20 °C for further analysis. A total of 30 samples (6 chicken at 5 time points) from treated and 30 samples from control chicken led to 12 individual TMT experiments with the inclusion of internal standards in each experiment.

High resolution LC-MS/MS analysis of TMT-labelled peptides was carried out using an Ultimate 3000 RSLCnano system (Dionex, Germering, Germany) coupled to a Q Exactive Plus mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). Peptides were loaded onto the trap column (C18 PepMap100, 5 µm, 100 A, 300 µm × 5 mm), desalted for 12 min at the flow rate of 15 uL/min and separated on the analytical column (PepMap™ RSLC C18, 50 cm × 75 μm) using linear gradient 5--45% mobile phase B (0.1% formic acid in 80% ACN) over 120 min, 45% to 90% for 2 min, held at 80% for 2 min and re-equilibrated at 5% B for 20 min at the flow rate of 300 nL/min. Loading solvent consisted of 0.1% formic acid and 2% ACN in water, while mobile phase A contained 0.1% formic acid in water. Ionisation was achieved using nanospray Flex ion source (Thermo Fisher Scientific, Bremen, Germany) containing a 10 μm-inner diameter SilicaTip emitter (New Objective, USA). The MS operated in positive ion mode using DDA Top8 method. The lock mass feature was not in use in this experiment. Full scan MS spectra were acquired in range from *m*/*z* 350.0 to *m*/*z* 1800.0 with a resolution of 70,000, 120 ms injection time, AGC target 1E6, a±2.0 Da isolation window and the dynamic exclusion 30 s. HCD fragmentation was performed at step collision energy (29% and 35% NCE) with a resolution of 17,500 and AGC target of 2E5. Precursor ions with unassigned charge state, as well as charge states of +1 and more than +7 were excluded from fragmentation. MS2 was operated in centroid mode.

For peptide identification and relative quantification the SEQUEST algorithm implemented into Proteome Discoverer (version 2.0., Thermo Fisher Scientific) was used. Database search against *Gallus gallus* FASTA files downloaded from NCBI database (7/12/2017, 46105 entries, NCBI *Gallus gallus* Annotation Release ID 103) was performed according to the following parameters: two trypsin missed cleavage sites, precursor and fragment mass tolerances of 10 ppm and 0.02 Da, respectively; carbamidomethyl (C) fixed peptide modification, oxidation (M), deamidation (N,Q) and TMT sixplex (K, peptide N-terminus) dynamic modifications. The false discovery rate (FDR) for peptide identification was calculated using the Percolator algorithm in the Proteome Discoverer workflow based on the search results against a decoy database and was set at 1% FDR. Only proteins with at least two unique peptides and less than 5% FDR were reported as reliable identification. Protein quantification was accomplished by correlating the relative intensities of reporter ions extracted from tandem mass spectra to that of the peptides selected for MS/MS fragmentation The internal standard was used to compare relative quantification results for each protein between the experiments (sixplexes). Peptide and protein identification data are shown in [Supplementary file 1](#s0065){ref-type="sec"}.

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository [@bib3] with the dataset identifier PXD009399.

4. Statistical and bioinformatics analysis of the chicken plasma proteome {#s0020}
=========================================================================

4.1. Statistics for proteomics {#s0025}
------------------------------

All statistics were performed using R (v3.4.3) [@bib4] under RStudio environment (v1.0.143) [@bib5]. Infection effect (saline versus LPS) and time effect in infection groups (0 h,12 h,24 h,48 h,72 h in saline and LPS separately) were considered for investigation. A peptide was not considered for the analysis if one of its group (infection, time or infection x time) had more of 50% of missing data after LC-MS identification and quantification. Filtered data are shown in [Supplementary file 2](#s0065){ref-type="sec"}.

A two-way ANOVA was performed to model the effect of treatment and time on the quantity of the peptides, using a linear regression model. Distribution of residuals generated by the ANOVA was accessed by a Shapiro-Wilk test. A Kruskal-Wallis test was performed to access the effect of treatment and time on peptides quantity using the R package "PMCMRplus" [@bib6]. Due to multiple comparisons performed, a local False Discovery Rate was applied using the R package "qvalue" [@bib7]. Each p-value was transformed by the function -log10(x). Obtained data are presented in [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}, as well as in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"} of Ref [@bib1].

Fold change between the 2 groups has been calculated by the function log2(Mean(Group2)/Mean(Group1)). A volcano plot was designed using the R package "plotly" [@bib8]. Plots were generated with the "ggplot2" package [@bib9]. Spearman׳s correlation were calculated to estimate the relationship between ELISA and LC-MS quantifications for the proteins AGP, SAA and OVT ([Fig. 6](#f0030){ref-type="fig"} of Ref [@bib1]).

All operations were scripted in R to assure the automatization of the statistics pipeline to all peptides.

4.2. Bioinformatics {#s0030}
-------------------

Proteins ID (*Gallus gallus*) were converted into Gene ID (*Gallus gallus*) by the platform DAVID (david-d.ncifcrf.gov/conversion.jsp) conversion tool. Gene Ontology enrichment analysis was performed using the Cytoscape (v3.6.0) [@bib10] plugin ClueGO (v2.5.0) [@bib11] on GO-Biological Processes (08/03/2018).

For treatment effect (LPS versus saline), two clusters of proteins differentially expressed between the 2 groups were set: one cluster for over-expressed proteins following LPS treatment, the other for proteins exhibiting lower-expression following LPS. The analysis was performed using the following parameters: evidence code=All, GO levels 3 to 15, minimal number of gene=3, minimal percentage of gene=3, Kappa score threshold=0.4, p-values corrected by Bonferroni step down.

For time effect, differentially expressed proteins with time were analyzed at once using the following parameters: evidence code=All, GO levels 3 to 8, minimal number of gene=3, minimal percentage of gene=3, Kappa score threshold=0.4, p-values corrected by Bonferroni step down.

The two lists of GO terms over-expressed in the context of group and time effects were submitted to an analysis by REVIGO (revigo.irb.hr) [@bib12] to remove redundant GO terms and group similar terms based on their description. For both analyses, the database used was *Gallus gallus*, with the SimReal semantic similarity measure.

Pathways of relationship between GO terms filtered according to REVIGO with their proteins/genes were designed on Cytoscape. Fold change data was included for the time effect analysis on samples from the LPS treated group. Pathway analysis data are shown in [Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}, as well as in Tables 3 and 4 of Ref [@bib1].

5. Measurement of acute phase protein concentrations {#s0035}
====================================================

5.1. Immunoassays {#s0040}
-----------------

The concentrations of AGP, SAA and OVT were determined in the plasma according to previously described procedures [@bib13]. The ELISA assays for chicken AGP and SAA were obtained from Life Diagnostics Inc (West Chester, USA). They were performed according to the manufacturer׳s instructions with a dilution factor for the plasma samples of 1:10,000 for AGP and 1:20 for SAA. Each individual sample was run in duplicate. The plasma concentration of OVT was assessed by radial immunodiffusion (RID) using specific antibody for chickens OVT as described previously \[50\]. Data are presented in Fig. 5 of Ref [@bib1].

5.2. Statistics for immunoassays {#s0045}
--------------------------------

Statistics on immunoassay were performed by non-parametric tests due to group size and distribution. Group effect was assessed by a Wilcoxon-test (2-sided), and a Kruskal-Wallis test was used to assess mixed effect Group x Time on all groups and Time effect on LPS and saline groups separately. For each time point (0 h/12 h/24 h/48 h/72 h), difference between LPS and saline was assessed by a Wilcoxon-test (2-sided) and fold change of expression calculated between times 12 h/24 h/48 h/72 h versus 0 h in LPS group. Correlation between these proteins was assessed on LPS group by a Spearman rank test. Immunoassays-related statistical data are shown in Tables 5 and 6 of Ref. [@bib1].
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[^1]: All proteins belong to the *Gallus gallus* proteome (UniprotKB).

[^2]: Proteins predicted in Gallus gallus, with no evidence of existence to date at protein, transcript or homology levels.

[^3]: GO terms were determined by Cytoscape/ClueGO and then analysed by REVIGO. GO terms in bold have been identified as the most representative of their GO group by the tool REVIGO.

[^4]: GO terms were determined by Cytoscape/ClueGO and then analysed by REVIGO. GO terms in bold have been identified as the most representative of their GO group by the tool REVIGO.

[^5]: NS: Not Significant (p\>0.05). Group effect was assessed between LPS and saline samples by Wilcoxon-test (2-sided). Mixed Group x Time and Time effects were assessed by a Kruskal-Wallis test.

[^6]: NS: Not Significant (p\>0.05). Differences were assessed with a Wilcoxon-test (2-sided).
